Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.7x | −6.2x | −0.5x | |
PEG Ratio | −0.26 | −0.33 | 0.00 | |
Price/Book | 4.3x | 3.9x | 2.6x | |
Price / LTM Sales | 389.1x | 53.4x | 3.2x | |
Upside (Analyst Target) | 48.5% | 90.9% | 44.7% | |
Fair Value Upside | Unlock | −5.6% | 5.7% | Unlock |